Midodrine for orthostatic hypotension: A systematic review and meta-analysis of clinical trials

Journal of General Internal Medicine

Volumn 28, Issue 11, 2013, Pages 1496-1503

  Parsaik, Ajay K ^a   Singh, Balwinder ^a   Altayar, Osama ^a   Mascarenhas, Soniya S ^b   Singh, Shannon K ^a   Erwin, Patricia J ^a   Murad, M Hassan ^a  

^a MAYO CLINIC   (United States)

^b London Training College   (United Kingdom)

Author keywords

efficacy; meta analysis; midodrine; orthostatic hypotension; safety; systematic review

Indexed keywords

MIDODRINE; PLACEBO;

CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG SAFETY; HUMAN; HYPERTENSION; MEAN ARTERIAL PRESSURE; META ANALYSIS; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PARESTHESIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFERENCE DATABASE; REFLEX; REVIEW; SCALP PRURITUS; SIDE EFFECT; STANDING; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; URINARY HESITANCY; URINE RETENTION;

BLOOD PRESSURE; CLINICAL TRIALS AS TOPIC; HUMANS; HYPOTENSION, ORTHOSTATIC; MIDODRINE; VASOCONSTRICTOR AGENTS;

EID: 84885950146     PISSN: 08848734     EISSN: 15251497     Source Type: Journal    
DOI: 10.1007/s11606-013-2520-3     Document Type: Review

References (26)

1. Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Auton Neurosci. 2011;161:46-8.
2. Low PA. Update on the evaluation, pathogenesis, and management of neurogenic orthostatic hypotension: introduction. Neurology. 1995;45:S4-5.
3. Low PA, Singer W. Management of neurogenic orthostatic hypotension: an update. Lancet Neurol. 2008;7:451-8.
4. Somberg JC. The midodrine withdrawal. Am J Ther. 2010;17:445.
5. Dhruva SS, Redberg RF. Accelerated approval and possible withdrawal of midodrine. JAMA. 2010;304:2172-3.
6. Mitka M. FDA takes slow road toward withdrawal of drug approved with fast-track process. JAMA. 2011;305:982-4.
7. Mitka M. Trials to address efficacy of midodrine 18 years after it gains FDA approval. JAMA. 2012;307:1124-7.
8. Somberg JC. The midodrine withdrawal. Am J Ther. 2010;17:445.
9. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas. 1960;20:37-46.
10. Higgins JP, Green S, Eds. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org 2011.
11. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ. 2004;328:1490.
12. Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schunemann HJ. What is "quality of evidence" and why is it important to clinicians? BMJ. 2008;336:995-8.
13. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88.
14. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557-60.
15. Fouad-Tarazi FM, Okabe M, Goren H. Alpha sympathomimetic treatment of autonomic insufficiency with orthostatic hypotension. Am J Med. 1995;99:604-10.
16. Jankovic J, Gilden JL, Hiner BC, et al. Neurogenic orthostatic hypotension: a double-blind, placebo-controlled study with midodrine. Am J Med. 1993;95:38-48.
17. Low PA, Gilden JL, Freeman R, Sheng KN, McElligott MA. Efficacy of midodrine vs. placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group. JAMA. 1997;277:1046-51.
18. Schrage WG, Eisenach JH, Dinenno FA, et al. Effects of midodrine on exercise-induced hypotension and blood pressure recovery in autonomic failure. J Appl Physiol. 2004;97:1978-84.
19. Wecht JM, Rosado-Rivera D, Handrakis JP, Radulovic M, Bauman WA. Effects of midodrine hydrochloride on blood pressure and cerebral blood flow during orthostasis in persons with chronic tetraplegia. Arch Phys Med Rehabil. 2010;91:1429-35.
20. Wright RA, Kaufmann HC, Perera R, et al. A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension. Neurology. 1998;51:120-4.
21. Axelrod FB, Krey L, Glickstein JS, Weider Allison J, Friedman D. Preliminary observations on the use of midodrine in treating orthostatic hypotension in familial dysautonomia. J Auton Nerv Syst. 1995;55:29-35.
22. Hoeldtke RD, Horvath GG, Bryner KD, Hobbs GR. Treatment of orthostatic hypotension with midodrine and octreotide. J Clin Endocrinol Metab. 1998;83:339-43.
23. Kaufmann H, Brannan T, Krakoff L, Yahr MD, Mandeli J. Treatment of orthostatic hypotension due to autonomic failure with a peripheral alpha-adrenergic agonist (midodrine). Neurology. 1988;38:951-6.
24. Logan IC, Witham MD. Efficacy of treatments for orthostatic hypotension: a systematic review. Age Ageing. 2012;41:587-94.
25. Pathak A, Raoul V, Montastruc JL, Senard JM. Adverse drug reactions related to drugs used in orthostatic hypotension: a prospective and systematic pharmacovigilance study in France. Eur J Clin Pharmacol. 2005;61:471-4.
26. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol. 2000;53:1119-29.